Ignite Creation Date:
2024-05-06 @ 11:04 AM
Last Modification Date:
2024-10-26 @ 12:39 PM
Study NCT ID:
NCT03425643
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-11-13
First Post:
2018-02-02
Brief Title:
Efficacy and Safety of Pembrolizumab MK-3475 With Platinum Doublet Chemotherapy as NeoadjuvantAdjuvant Therapy for Participants With Resectable Stage II IIIA and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer MK-3475-671KEYNOTE-671
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-04-24
Start Date Type:
ACTUAL
Primary Completion Date:
2023-07-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-06-29
Completion Date Type:
ESTIMATED
First Submit Date:
2018-02-02
First Submit QC Date:
February 2 2018
Study First Post Date:
2018-02-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-11
Last Update Post Date:
2023-11-13
Last Update Post Date Type:
ACTUAL